Quick Answer
ABBOTT LABORATORIES reported Cash and Equivalents of $8.52 billion for fiscal year 2025.
ABBOTT LABORATORIES Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.52B | +11.9% |
| 2024 | $7.62B | +10.4% |
| 2023 | $6.90B | -30.2% |
| 2022 | $9.88B | +0.8% |
| 2021 | $9.80B | +43.3% |
| 2020 | $6.84B | +77.2% |
| 2019 | $3.86B | +0.4% |
| 2018 | $3.84B | -59.1% |
| 2017 | $9.41B | -49.5% |
| 2016 | $18.62B | +272.3% |
| 2015 | $5.00B | +23.1% |
| 2014 | $4.06B | +16.9% |
| 2013 | $3.48B | -67.8% |
| 2012 | $10.80B | +58.5% |
| 2011 | $6.81B | +86.8% |
| 2010 | $3.65B | -58.6% |
| 2009 | $8.81B | +114.2% |
| 2008 | $4.11B | +67.4% |
| 2007 | $2.46B | +371.3% |
| 2006 | $521.19M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.51B | -0.6% | +8.1% |
| June 30, 2025 | $6.95B | -0.5% | +6.4% |
| March 31, 2025 | $6.53B | +3.9% | -14.2% |
| December 31, 2024 | $7.62B | +10.4% | +0.8% |
| September 30, 2024 | $7.56B | +12.7% | +8.2% |
| June 30, 2024 | $6.99B | -10.8% | +11.2% |
| March 31, 2024 | $6.28B | -31.4% | -8.9% |
| December 31, 2023 | $6.90B | -30.2% | +2.8% |
- ABBOTT LABORATORIES showed an increase of +11.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2006–2025 period, ABBOTT LABORATORIES’s cash and equivalents has grown by 1535.1% (from $521.19 million to $8.52 billion).
- The most recent figure is from ABBOTT LABORATORIES’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: